NEW YORK, September 29, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Geron Corporation (NASDAQ: GERN), BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), Array BioPharma Inc.
(NASDAQ: ARRY), Cerner Corporation (NASDAQ: CERN),
Arrowhead Research Corporation (NASDAQ: ARWR). On
Monday, September 28, 2015, NASDAQ
ended at 4,543.97 down 3.04%, Dow Jones declined 1.92%, to finish
the day at 16,001.89, and the S&P closed at 1,881.77, down
2.57%. Register for your complimentary reports at the links given
below.
--
Geron Corp
--
Geron Corp's stock edged lower by 5.57% to close Monday's
session at USD 2.88. The company's
shares oscillated between USD 2.82 and USD
3.04. The stock recorded a trading volume of 3.46 million
shares, which was above its 50-day daily average volume of 2.78
million shares and above its 52-week average volume of 3.46 million
shares. Over the last three days, Geron Corp's shares have declined
by 13.25% and in the past one week it has moved down 14.54%.
Furthermore, over the last three months, the stock has lost 29.58%
and in the past six months, the shares have shed 25.58%. The stock
is trading at a price to book ratio of 3.85 while the historical PB
ratio is near to 3.91. Sign up and read the free notes on GERN at:
http://www.aciassociation.com/GERN.pdf
--
BioMarin Pharmaceutical Inc.
--
The stock of BioMarin Pharmaceutical Inc. lost 8.57% to close
Monday's session at USD 99.38. The
shares of the company moved in the range of USD 95.84 and USD
107.38. A trading volume of 3.35 million shares was
recorded, which was greater than its 150-day daily average volume
of 1.41 million shares and above its 52-week average volume of 1.34
million shares. Over the last five days, BioMarin Pharmaceutical
Inc.'s shares have declined by 18.60% and in the past one month, it
has lost 22.42%. Additionally, over the last three months, the
stock has declined 24.89% and in the past six months, the shares
have registered a loss of 23.04%. The stock is trading at a price
to book ratio of 6.79 while the historical PB ratio is close to
8.82. Register for free on ACI Association and access the latest
research on BMRN at:
http://www.aciassociation.com/BMRN.pdf
--
Array Biopharma Inc.
--
Array Biopharma Inc.'s stock decreased by 3.04% to close
Monday's session at USD 4.78. The
company's shares fluctuated in the range of USD 4.60 and USD
4.97. A total of 3.25 million shares exchanged hands, which
surpassed its 50-day daily average volume of 1.77 million shares
and was above its 52-week average volume of 2.18 million shares.
Over the last three days Array Biopharma Inc.'s shares have
declined by 6.09% and in the past one week it has moved down
10.82%. Furthermore, over the last three months, the stock has lost
2.29% and in the past six months, the shares have shed 36.60%.
Further, the company is trading at a price to earnings ratio of
478.00 and a price to book ratio of 15.93. This compares to a
historical PE ratio of 109.04 and a historical PB ratio close to
24.02. The complete research on ARRY is available for free at:
http://www.aciassociation.com/ARRY.pdf
--
Cerner Corp
--
Cerner Corp's stock slipped by 4.22% to close Monday's session
at USD 58.15. The company's shares
oscillated between USD 58.01 and USD
60.75. The stock recorded a trading volume of 3.23 million
shares, which was above its 50-day daily average volume of 2.70
million shares and above its 52-week average volume of 1.81 million
shares. Over the last five days, Cerner Corp's shares have declined
by 8.40% and in the past one month, it has lost 5.65%. In addition,
over the last three months, the stock has lost 14.77% and year to
date, the shares have shed 10.07%. Further, the company is trading
at a price to earnings ratio of 40.38 and a price to book ratio of
5.19. This compares to a historical PE ratio of 43.37 and a
historical PB ratio close to 6.24. Free in-depth research on CERN
is available at: http://www.aciassociation.com/CERN.pdf
--
Arrowhead Research Corp
--
Arrowhead Research Corp's stock declined 13.22% to close
Monday's session at USD 6.30. The
share price vacillated between USD 6.23 and
USD 7.39. The stock recorded a trading volume of 3.11
million shares, which was above its 50-day daily average volume of
1.88 million shares and above its 52-week average volume of 2.26
million shares. Over the last three days Arrowhead Research Corp's
shares have declined by 6.53% and in the past one week it has moved
down 14.98%. Moreover, in the last six months, the stock has lost
10.00% and year to date, the shares have shed 14.63%. The stock is
trading at a price to book ratio of 2.85 while the historical PB
ratio is close to 4.85. The complimentary notes on ARWR can be
downloaded in PDF format at:
http://www.aciassociation.com/ARWR.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been
sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com